



## **Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference**

November 10, 2017

DURHAM, N.C., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapor, President and Chief Executive Officer, will present a company overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 8:00 a.m. GMT (3:00 a.m. EST) in London.

A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, [www.dova.com](http://www.dova.com). Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.

### **About Dova Pharmaceuticals, Inc.**

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova's lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been submitted to the FDA for this initial indication.

### **Contacts**

Doug Blankenship  
(919) 748-5975  
[dblankenship@dova.com](mailto:dblankenship@dova.com)

Westwicke Partners  
John Woolford  
(443) 213-0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

Source: Dova Pharmaceuticals, Inc.